Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03311373 · ClinicalTrials.gov registry record · Phase 1

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

A Phase 1 study, sponsored by Pearl Therapeutics.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target

NCT03311373 is a Phase 1 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 56 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03311373, a Phase 1 study, has completed, sponsored by Pearl Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target

Study Summary

Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

Interventions

  • DRUG Regimen A
  • DRUG Regimen B
  • DRUG Regimen C
  • DRUG Regimen D

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2017-10-17
Est. Completion 2017-12-15
Phase Phase 1

Sponsor

Pearl Therapeutics

31 total trials

What the Registry Record Tells You About NCT03311373

The ClinicalTrials.gov registry entry for NCT03311373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Regimen A is the first listed.

NCT03311373 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03311373 about?

NCT03311373 is a clinical study titled "A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010". Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

What is the current status of trial NCT03311373?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2017-10-17. Estimated completion is 2017-12-15.

What interventions are being tested in trial NCT03311373?

The interventions under investigation include: Regimen A (DRUG), Regimen B (DRUG), Regimen C (DRUG), Regimen D (DRUG).

Who is sponsoring clinical trial NCT03311373?

This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.